Healthcare provider profile · identity verified

David J. Kehas, MD

Family Practice · HOOKSETT, NH · NPI 1477562353

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	496	134
Levothyroxine Sodium	Levothyroxine Sodium	374	82
Rosuvastatin Calcium	Rosuvastatin Calcium	223	57
Losartan Potassium	Losartan Potassium	169	45
Lisinopril	Lisinopril	149	41
Albuterol Sulfate Hfa	Albuterol Sulfate	145	45
Omeprazole	Omeprazole	141	35
Metformin Hcl	Metformin Hcl	136	39
Amlodipine Besylate	Amlodipine Besylate	130	40
Metoprolol Succinate	Metoprolol Succinate	123	40
Gabapentin	Gabapentin	116	27
Pantoprazole Sodium	Pantoprazole Sodium	85	28
Hydrochlorothiazide	Hydrochlorothiazide	82	25
Montelukast Sodium	Montelukast Sodium	82	21
Pravastatin Sodium	Pravastatin Sodium	78	22
Furosemide	Furosemide	77	23
Trazodone Hcl	Trazodone Hcl	77	21
Eliquis	Apixaban	73	17
Metoprolol Tartrate	Metoprolol Tartrate	72	20
Lorazepam	Lorazepam	64	16
Potassium Chloride	Potassium Chloride	63	11
Duloxetine Hcl	Duloxetine Hcl	62	14
Metformin Hcl Er	Metformin Hcl	58	15
Escitalopram Oxalate	Escitalopram Oxalate	57	17
Tamsulosin Hcl	Tamsulosin Hcl	57	16
Tramadol Hcl	Tramadol Hcl	52	suppressed
Simvastatin	Simvastatin	51	17
Atenolol	Atenolol	45	12
Sertraline Hcl	Sertraline Hcl	45	14
Jardiance	Empagliflozin	44	12
Prednisone	Prednisone	43	35
Venlafaxine Hcl Er	Venlafaxine Hcl	43	suppressed
Pregabalin	Pregabalin	42	suppressed
Carvedilol	Carvedilol	41	13
Hydroxyzine Hcl	Hydroxyzine Hcl	41	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	39	suppressed
Rybelsus	Semaglutide	39	suppressed
Diazepam	Diazepam	37	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	37	31
Meloxicam	Meloxicam	37	17
Ropinirole Hcl	Ropinirole Hcl	37	suppressed
Allopurinol	Allopurinol	36	suppressed
Bupropion Xl	Bupropion Hcl	35	12
Clopidogrel	Clopidogrel Bisulfate	35	12
Glipizide Er	Glipizide	35	suppressed
Xarelto	Rivaroxaban	35	suppressed
Finasteride	Finasteride	34	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	34	suppressed
Warfarin Sodium	Warfarin Sodium	33	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	suppressed
Mounjaro	Tirzepatide	30	suppressed
Chlorthalidone	Chlorthalidone	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	11
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Clonazepam	Clonazepam	26	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	26	suppressed
Ibuprofen	Ibuprofen	26	suppressed
Meclizine Hcl	Meclizine Hcl	26	suppressed
Valsartan	Valsartan	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Ozempic	Semaglutide	25	suppressed
Famotidine	Famotidine	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Methocarbamol	Methocarbamol	22	suppressed
Ramipril	Ramipril	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	14
Synthroid	Levothyroxine Sodium	21	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Topiramate	Topiramate	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Cephalexin	Cephalexin	19	17
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Clotrimazole	Clotrimazole	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Glipizide	Glipizide	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Dexlansoprazole Dr	Dexlansoprazole	17	suppressed
Nystatin	Nystatin	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	15
Amoxicillin	Amoxicillin	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Klor-Con M20	Potassium Chloride	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Estradiol	Estradiol	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Bydureon Bcise	Exenatide Microspheres	12	suppressed
Creon	Lipase/Protease/Amylase	12	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Naproxen	Naproxen	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	11	suppressed
Oxycontin	Oxycodone Hcl	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error